GB0329620D0 - EP2 receptor agonists - Google Patents

EP2 receptor agonists

Info

Publication number
GB0329620D0
GB0329620D0 GBGB0329620.9A GB0329620A GB0329620D0 GB 0329620 D0 GB0329620 D0 GB 0329620D0 GB 0329620 A GB0329620 A GB 0329620A GB 0329620 D0 GB0329620 D0 GB 0329620D0
Authority
GB
United Kingdom
Prior art keywords
receptor agonists
sub
receptor
agonism
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0329620.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmagene Laboratories Ltd
Original Assignee
Pharmagene Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Laboratories Ltd filed Critical Pharmagene Laboratories Ltd
Priority to GBGB0329620.9A priority Critical patent/GB0329620D0/en
Publication of GB0329620D0 publication Critical patent/GB0329620D0/en
Priority to DE602004019697T priority patent/DE602004019697D1/de
Priority to AT04806216T priority patent/ATE423765T1/de
Priority to EP04806216A priority patent/EP1716113B1/en
Priority to PCT/GB2004/005421 priority patent/WO2005061449A1/en
Priority to US10/583,896 priority patent/US20080045596A1/en
Priority to JP2006546323A priority patent/JP2007515467A/ja
Priority to ES04806216T priority patent/ES2322765T3/es
Priority to US11/019,133 priority patent/US20050209336A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB0329620.9A 2003-12-22 2003-12-22 EP2 receptor agonists Ceased GB0329620D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0329620.9A GB0329620D0 (en) 2003-12-22 2003-12-22 EP2 receptor agonists
DE602004019697T DE602004019697D1 (de) 2003-12-22 2004-12-22 Ep2-rezeptoragonisten
AT04806216T ATE423765T1 (de) 2003-12-22 2004-12-22 Ep2-rezeptoragonisten
EP04806216A EP1716113B1 (en) 2003-12-22 2004-12-22 Ep2- receptor agonists
PCT/GB2004/005421 WO2005061449A1 (en) 2003-12-22 2004-12-22 Ep2 receptor agonists
US10/583,896 US20080045596A1 (en) 2003-12-22 2004-12-22 Ep2 Receptor Agonists
JP2006546323A JP2007515467A (ja) 2003-12-22 2004-12-22 Ｅｐ２受容体アゴニスト
ES04806216T ES2322765T3 (es) 2003-12-22 2004-12-22 Agonistas del receptor ep2.
US11/019,133 US20050209336A1 (en) 2003-12-22 2004-12-22 EP2 receptor agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0329620.9A GB0329620D0 (en) 2003-12-22 2003-12-22 EP2 receptor agonists

Publications (1)

Publication Number Publication Date
GB0329620D0 true GB0329620D0 (en) 2004-01-28

Family

ID=30776234

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0329620.9A Ceased GB0329620D0 (en) 2003-12-22 2003-12-22 EP2 receptor agonists

Country Status (8)

Country Link
US (2) US20050209336A1 (https=)
EP (1) EP1716113B1 (https=)
JP (1) JP2007515467A (https=)
AT (1) ATE423765T1 (https=)
DE (1) DE602004019697D1 (https=)
ES (1) ES2322765T3 (https=)
GB (1) GB0329620D0 (https=)
WO (1) WO2005061449A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
JP5410271B2 (ja) * 2006-04-04 2014-02-05 アラーガン インコーポレイテッド 緑内障治療用プロスタグランジン化合物
US7491844B2 (en) 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US8722726B2 (en) 2007-01-25 2014-05-13 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US9365485B2 (en) 2007-01-25 2016-06-14 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US7781465B2 (en) * 2007-08-21 2010-08-24 Allergan, Inc. Therapeutic oxazolidinones and thiazolidinones
JP2011510965A (ja) * 2008-02-05 2011-04-07 アステランド ユーケー リミテッド 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体
HUE042839T2 (hu) 2008-03-12 2019-07-29 Ube Industries Piridilaminoecetsav vegyületek
EP2408444A4 (en) 2009-03-19 2012-09-26 Fate Therapeutics Inc COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE
HRP20160104T1 (hr) 2009-03-30 2016-03-25 Ube Industries Farmaceutski pripravak za liječenje ili prevenciju glaukoma
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
JPWO2011030864A1 (ja) * 2009-09-11 2013-02-07 宇部興産株式会社 アニリン化合物
AU2013306012B2 (en) 2012-08-21 2018-02-08 Allergan, Inc. Process for the synthesis of substituted gamma lactams

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5576347A (en) * 1994-11-14 1996-11-19 Sredni; Benjamin Method of treating gastric ulcers
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
SE9900025D0 (sv) * 1999-01-08 1999-01-08 Synphora Ab Method and composition for treatment of female sexual dysfunction
DE60118628T2 (de) * 2001-10-26 2007-02-15 Allergan, Inc., Irvine Omega-cycloalkyl 17-heteroaryl prostaglandin e2 analogen als ep2-rezeptor agonisten
MXPA04004164A (es) * 2001-11-05 2004-09-06 Allergan Inc Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2.

Also Published As

Publication number Publication date
JP2007515467A (ja) 2007-06-14
WO2005061449A1 (en) 2005-07-07
EP1716113A1 (en) 2006-11-02
US20080045596A1 (en) 2008-02-21
DE602004019697D1 (de) 2009-04-09
EP1716113B1 (en) 2009-02-25
ATE423765T1 (de) 2009-03-15
ES2322765T3 (es) 2009-06-26
US20050209336A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
GB0329620D0 (en) EP2 receptor agonists
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
DE60112974D1 (en) Carbolinderivate
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
EP2289894A3 (en) Pyrrolo-triazine compounds useful as kinase inhibitors
ATE383856T1 (de) (4-hydroxyphenyl)-1h-indol-3-carbaldehydoxim- derivative als östrogenagentien
ES2187282A1 (es) Mezclas estabilizantes para materiales organicos.
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
EP1889842A4 (en) HETEROCYCLIC CONNECTION
MX2007006374A (es) Derivados del 5-hidroxi-benzotiazol que tienen actividad agonista del adrenoreceptor-beta-2.
JO2578B1 (en) Compounds Theophene benzimidazole
MXPA03007142A (es) Derivados de carbolina.
MXPA02012076A (es) Compuestos quimicos.
MXPA03002911A (es) Compuestos quimicos.
TW200745094A (en) ATM inhibitor
MXPA02012659A (es) Derivados de pirazindiona condensados.
PL1805170T3 (pl) Inhibitory MIF
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
TW200724539A (en) Benzimidazole derivative and use thereof
MY144338A (en) Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)